Thomas Appio, Bausch Health CEO
August 1, 2022 01:39 PM EDT
Pharma
Law

Bausch Health as­serts push to 'vig­or­ous­ly' de­fend Xi­fax­an patent lit­i­ga­tion 

Kyle LaHucik

Senior Reporter

Bausch Health will con­tin­ue lit­i­gat­ing over its Xi­fax­an drug, threat­en­ing to ap­peal all the way up to the US Court of Ap­peals for the Fed­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times